# NUC in Preventing HBV Reactivation in HCV/HBV Co-infected Patients Receiving DAA for CHC

> **NCT04405011** · NA · UNKNOWN · sponsor: **National Taiwan University Hospital** · enrollment: 60 (estimated)

## Conditions studied

- HBV/HCV Co-infection

## Interventions

- **DRUG:** 24-week Entecavir
- **DRUG:** 12-week Entecavir

## Key facts

- **NCT ID:** NCT04405011
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08-01
- **Primary completion:** 2020-12-28
- **Final completion:** 2020-12-28
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2020-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04405011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04405011, "NUC in Preventing HBV Reactivation in HCV/HBV Co-infected Patients Receiving DAA for CHC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04405011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*